Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients [0.03%]
纠正：Teclistamab治疗多发性骨髓瘤患者巨细胞病毒再活化的临床结果及危险因素
Hira Cheema,Asis Shrestha,Syed Naqvi et al.
Hira Cheema et al.
Published Erratum
Blood cancer journal. 2026 Aug 7;16(1):133. DOI:10.1038/s41408-026-01593-w 2026
Post-transplant hypomethylating agents plus venetoclax maintenance improves survival in high-risk myeloid malignancies: A matched cohort study [0.03%]
移植后低甲基化药物联合venetoclax维持治疗可改善高危髓系恶性肿瘤患者的生存率：一项配对队列研究
Haley Thigpen,Kendall Diebold,Todd Mudd et al.
Haley Thigpen et al.
Treatment of adult acute lymphoblastic leukemia-a therapeutic revolution in the making [0.03%]
成人急性淋巴细胞白血病的治疗：一场正在酝酿的治疗革命
Hagop Kantarjian,Ayalew Tefferi
Hagop Kantarjian
Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine [0.03%]
维奈托克、阿扎胞苷和G-CSF根除CBFB::MYH11 AML患者分子残留病：超高剂量阿糖胞苷治疗失败患者的靶向疗法
Ting Shi,Ruicong Xue,Jing Jia et al.
Ting Shi et al.
Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study [0.03%]
伊索替康固定剂量联合长春地平和泼尼松方案作为成人新诊断B细胞急性淋巴细胞白血病诱导治疗的临床研究
Lei Ju,Sifeng Gao,JiLei Zhang et al.
Lei Ju et al.
Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes [0.03%]
移植前分子国际预后评分降低与骨髓衰竭性疾病患者的移植结局改善无关
Masataka Sakashita,Junya Kanda,Keiichiro Hattori et al.
Masataka Sakashita et al.
Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia [0.03%]
奥雷巴替尼联合免疫治疗与奥雷巴替尼联合异基因造血干细胞移植治疗新诊断费城染色体阳性急性淋巴细胞白血病成人患者的效果比较研究
Chenying Li,Hongyan Tong,Huafeng Wang et al.
Chenying Li et al.
Selinexor for myelofibrosis or a drug in search of a disease? [0.03%]
选择性核转运蛋白XPO1抑制剂塞利尼索在骨髓纤维化中定位思考
Naseema Gangat,Ayalew Tefferi
Naseema Gangat
Selinexor for the Treatment of Myelofibrosis. SVR35- spleen volume reduction ≥ 35%, TSS- total symptom score. © 2026. The Author(s).
SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS [0.03%]
SECURE研究：偶然发现的MGUS患者的英国前瞻性队列基线结果
Elizabeth Knight,Anupama Krishnamoorthi,Berrin Balik et al.
Elizabeth Knight et al.
Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors [0.03%]
新型药物Selinexor治疗jak抑制剂难治/不耐受的骨髓纤维化患者有效且安全
Srinivas K Tantravahi,Andrea A Ellero,Ami B Patel et al.
Srinivas K Tantravahi et al.